AML express testing: leveraging next-generation sequencing for critical gene analysis

Acute myeloid leukemia (AML) is the most common form of leukemia, with approximately 20,800 new cases expected in the United States in 2024 and a 5-year survival rate of only 32% [1]. This aggressive cancer is characterized by rapid and uncontrolled proliferation of immature myeloid cells in the blood and bone marrow. AML progresses rapidly, often within weeks or months, and requires prompt diagnosis and intervention to avoid life-threatening complications.

This White Paper outlines the urgency of AML diagnosis and treatment and the impact genetic testing could play, before introducing the AML Express Assay, which leverages next-generation sequencing technology to test relevant biomarkers.

CORP-MRKT-0188 AML Express White Paper (1)

This content was supplied by NEOGENOMICS.